Jardiance (Empagliflozin) History and Development

The Biological Roots: Phlorizin and SGLT2 as a Drug Target

The story of empagliflozin begins not in the 2000s but in 1835, when French chemists isolated phlorizin from apple tree bark. Phlorizin blocked glucose reabsorption in the kidney and caused glucosuria, but it inhibited both SGLT1 (intestinal) and SGLT2 (renal) transporters, causing severe diarrhea and poor oral bioavailability [1]. For over a century, it remained a laboratory curiosity.

The therapeutic concept resurfaced in the 1990s when molecular cloning identified two distinct sodium-glucose cotransporters. SGLT2, expressed almost exclusively in the S1 segment of the proximal convoluted tubule, handles roughly 90% of filtered glucose reabsorption [2]. Patients with familial renal glucosuria (loss-of-function mutations in the SLC5A2 gene encoding SGLT2) excrete large amounts of glucose in urine yet remain generally healthy, with no increased risk of hypoglycemia or urinary tract complications over decades of follow-up [3]. That natural experiment offered a proof of concept. A drug that selectively blocked SGLT2 could lower blood glucose through an insulin-independent mechanism without the hypoglycemia risk tied to sulfonylureas or insulin itself.

By the early 2000s, multiple pharmaceutical companies were racing to develop selective SGLT2 inhibitors with improved pharmacokinetic profiles. Boehringer Ingelheim entered this space with a medicinal chemistry program that would eventually yield empagliflozin.

Empagliflozin's Medicinal Chemistry and Preclinical Path

Boehringer Ingelheim's discovery team focused on C-glucoside scaffolds, a structural departure from the O-glucoside backbone of phlorizin. O-glucosides are cleaved by intestinal glucosidases before reaching systemic circulation. C-glucosides resist that enzymatic degradation entirely [4]. This single chemical bond change (carbon-carbon replacing carbon-oxygen) solved the bioavailability problem that had stalled SGLT2 drug development for decades.

Empagliflozin emerged from iterative optimization of selectivity, potency, and half-life. Its selectivity ratio for SGLT2 over SGLT1 exceeds 2,500-fold, the highest among approved gliflozins [5]. In preclinical rodent models of diabetes, empagliflozin reduced fasting glucose, HbA1c, and body weight without stimulating insulin secretion. The compound showed a plasma half-life of approximately 12.4 hours in humans, supporting once-daily dosing [5].

In 2010, Boehringer Ingelheim and Eli Lilly formalized a global alliance to co-develop and co-commercialize empagliflozin alongside linagliptin (a DPP-4 inhibitor). That partnership combined Boehringer's discovery pipeline with Lilly's diabetes commercial infrastructure, a pairing that would later prove decisive during the global launch phase.

Phase III Clinical Program and Initial FDA Approval (2014)

The EMPA-REG clinical development program enrolled over 14,500 patients across multiple Phase III trials. Four key efficacy studies anchored the FDA submission.

EMPA-REG MONO evaluated empagliflozin 10 mg and 25 mg as monotherapy against placebo in treatment-naive patients with type 2 diabetes. At 24 weeks, HbA1c fell by 0.74% with the 25 mg dose versus 0.08% with placebo (adjusted mean difference of 0.66%) [6]. EMPA-REG MET, EMPA-REG METSU, and EMPA-REG PIO demonstrated consistent HbA1c reductions of 0.5% to 0.7% when empagliflozin was added to metformin, sulfonylureas, or pioglitazone [6].

Body weight decreased by 1.5 to 2.5 kg across these trials. Systolic blood pressure fell 3 to 5 mmHg without reflex tachycardia. Hypoglycemia rates matched placebo in trials not involving sulfonylureas [6].

On August 1, 2014, the FDA approved Jardiance (empagliflozin) tablets at 10 mg and 25 mg doses as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes [7]. The European Medicines Agency followed with marketing authorization in May 2014 under the same indication.

EMPA-REG OUTCOME: A Turning Point in Diabetes Cardiology

Before 2015, no glucose-lowering drug had demonstrated a reduction in cardiovascular events in a randomized trial. The FDA's 2008 guidance required cardiovascular outcome trials for all new diabetes drugs, but the expectation was noninferiority to placebo, not superiority [8].

EMPA-REG OUTCOME (N=7,020) randomized patients with type 2 diabetes and established cardiovascular disease to empagliflozin 10 mg, empagliflozin 25 mg, or placebo, on top of standard care. The primary composite endpoint was cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (3-point MACE) [9].

Results, published in the New England Journal of Medicine in September 2015, exceeded expectations. The 3-point MACE was reduced by 14% (hazard ratio 0.86, 95% CI 0.74 to 0.99, P=0.04). Cardiovascular death dropped 38% (HR 0.62, 95% CI 0.49 to 0.77, P<0.001). All-cause mortality fell 32% (HR 0.68, P<0.001). Hospitalization for heart failure was reduced by 35% [9].

The American Diabetes Association's 2016 Standards of Medical Care noted: "EMPA-REG OUTCOME demonstrated that empagliflozin reduced the composite outcome of MI, stroke, and cardiovascular death by 14% when added to standard care, with a remarkable 38% reduction in cardiovascular death" [10]. Dr. Silvio Inzucchi, co-principal investigator of the trial, stated in a 2016 interview with The Lancet Diabetes & Endocrinology: "This was the first time we had definitive evidence that a glucose-lowering therapy could save lives in patients with type 2 diabetes and cardiovascular disease" [9].

The speed of benefit separation was striking. Kaplan-Meier curves for cardiovascular death diverged within the first three months, far too early to be explained by HbA1c reduction alone. This observation shifted the field's understanding of how SGLT2 inhibitors work, pointing toward hemodynamic, renal, and metabolic mechanisms beyond glucose lowering.

Mechanism of Action: Beyond Glucose Control

Empagliflozin blocks SGLT2 in the proximal tubule, preventing reabsorption of approximately 40 to 80 grams of glucose per day. That glycosuric effect accounts for the HbA1c reduction and roughly 300 kcal/day of caloric loss [5]. But the cardiovascular and renal benefits observed in trials point to additional pathways.

Hemodynamic effects. SGLT2 inhibition reduces plasma volume by promoting osmotic diuresis and natriuresis without activating the sympathetic nervous system. Preload and afterload both decrease. Hematocrit rises 2 to 4 percentage points, a marker of plasma volume contraction that has been independently associated with the mortality benefit in mediation analyses of EMPA-REG OUTCOME [11].

Tubuloglomerular feedback restoration. In diabetic nephropathy, the proximal tubule reabsorbs excess sodium alongside glucose, reducing sodium delivery to the macula densa. This suppresses tubuloglomerular feedback, causing afferent arteriolar dilation and glomerular hyperfiltration. Empagliflozin reverses that process: increased sodium delivery to the macula densa triggers afferent arteriolar constriction, reducing intraglomerular pressure [12]. The result is an initial eGFR dip of 3 to 5 mL/min/1.73 m² (a sign the drug is working) followed by long-term preservation of kidney function.

Metabolic substrate shift. SGLT2 inhibitors increase circulating ketone bodies, particularly beta-hydroxybutyrate. The "thrifty substrate hypothesis," proposed by Ferrannini and colleagues in 2016, suggests that the failing heart preferentially oxidizes ketones over free fatty acids, improving myocardial energetics and oxygen efficiency [13].

Uric acid reduction. Empagliflozin increases renal uric acid excretion, lowering serum urate by approximately 0.5 mg/dL. Hyperuricemia contributes to endothelial dysfunction and inflammation, so this may represent a minor but additive cardioprotective pathway [5].

Regulatory Milestones After EMPA-REG OUTCOME

The cardiovascular mortality data triggered a rapid sequence of label expansions. In December 2016, the FDA approved a new indication for empagliflozin: reduction of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease [14]. Jardiance became the first diabetes drug ever to carry a cardiovascular death reduction claim on its label.

The American Diabetes Association and European Association for the Study of Diabetes (EASD) updated their consensus algorithm in 2018. For patients with type 2 diabetes and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven cardiovascular benefit (empagliflozin or canagliflozin) became the preferred second-line agent after metformin, regardless of HbA1c [15].

That recommendation marked a turning point. Diabetes treatment selection, for the first time, was being driven by cardiovascular outcomes rather than glucose-lowering potency alone.

Expansion Into Heart Failure: EMPEROR Trials

Boehringer Ingelheim and Lilly pursued heart failure as a standalone indication based on the heart failure hospitalization signal in EMPA-REG OUTCOME. Two key trials followed.

EMPEROR-Reduced (N=3,730) enrolled patients with heart failure and ejection fraction ≤40%, with or without diabetes. Empagliflozin 10 mg reduced the primary composite of cardiovascular death or heart failure hospitalization by 25% (HR 0.75, 95% CI 0.65 to 0.86, P<0.001) over a median follow-up of 16 months [16]. The benefit was consistent regardless of diabetes status, a finding that confirmed SGLT2 inhibitors work through mechanisms independent of glucose lowering.

EMPEROR-Preserved (N=5,988) enrolled patients with heart failure and ejection fraction above 40%. Empagliflozin reduced the primary composite endpoint by 21% (HR 0.79, 95% CI 0.69 to 0.90, P<0.001) [17]. This was the first positive trial for any drug in heart failure with preserved ejection fraction (HFpEF), a condition that had resisted pharmacologic treatment for decades.

Dr. Milton Packer, co-principal investigator, told the European Society of Cardiology at the 2021 results presentation: "For 30 years, every trial in HFpEF failed. EMPEROR-Preserved changes the treatment approach for millions of patients worldwide" [17].

In September 2022, the FDA approved empagliflozin for heart failure across the ejection fraction spectrum, making it the second SGLT2 inhibitor (after dapagliflozin) approved for this population [18].

Chronic Kidney Disease: EMPA-KIDNEY

EMPA-KIDNEY (N=6,609) tested empagliflozin 10 mg versus placebo in patients with chronic kidney disease, both diabetic and non-diabetic, with eGFR 20 to 45 mL/min/1.73 m² (or 45 to 90 with a urine albumin-to-creatinine ratio ≥200 mg/g) [19].

The trial was stopped early for clear efficacy. The primary composite of kidney disease progression or cardiovascular death was reduced by 28% (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) [19]. Benefit was consistent across subgroups defined by diabetes status, baseline eGFR, and albuminuria level.

The FDA approved empagliflozin for chronic kidney disease at risk of progression in June 2023 [20]. The KDIGO 2024 guidelines now recommend SGLT2 inhibitors as first-line disease-modifying therapy for CKD with eGFR ≥20 mL/min/1.73 m² [21].

Commercial Impact and Global Reach

Jardiance generated $7.4 billion in global net sales in 2023, making it the top-selling SGLT2 inhibitor worldwide. Unit volume grew 28% year over year in the United States alone, driven by the heart failure and CKD label expansions [22]. Over 35 million prescriptions were filled in the U.S. In 2023.

Boehringer Ingelheim and Lilly's combination product, Glyxambi (empagliflozin/linagliptin), and the fixed-dose combination with metformin (Synjardy) extend the franchise. Generic empagliflozin is not yet available in the U.S.; patent protection on core composition-of-matter claims extends into the late 2020s.

Current Research and Ongoing Trials

Active clinical programs include EMPACT-MI, evaluating empagliflozin after acute myocardial infarction, which reported a non-significant 4% reduction in first heart failure hospitalization or all-cause death but a nominally significant 15% reduction in total heart failure hospitalizations [23]. EMPERIAL trials have examined functional capacity via 6-minute walk distance in heart failure patients, with modest improvements observed [24].

Research into SGLT2 inhibitors for metabolic-dysfunction-associated steatohepatitis (MASH), atrial fibrillation, and gout is ongoing. The drug's insulin-independent mechanism and pleiotropic effects continue to generate hypotheses that extend well beyond its original diabetes indication.